Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 7NSCLC 2Advanced Non-Small Cell Lung Cancer 2Stomach Neoplasms 1Radiation Injuries 1Pancoast Syndrome 1Non-small Cell Lung Cancer Stage â…¡ 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Advanced NSCLC With EGFR Mutation 1

Interventions

Docetaxel 6Gemcitabine 3Carboplatin 3lorlatinib 2cemiplimab 2Vinorelbine 2S 1 (combination) 2Pemetrexed 2Erlotinib Hydrochloride 2Cisplatin 2Cetuximab 2zimberelimab 1surufatinib 1sintilimab 1quemliclustat 1pemigatinib 1pembrolizumab 1nimotuzumab 1fludarabine 1WW Domain-Containing Oxidoreductase 1Paclitaxel 1Interleukin-2 1Gene Expression Profiling 1Drug Therapy 1Cyclophosphamide 1Capecitabine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Non-Small Cell Lung Cancer × S 1 (combination) × Thoracic × Clear all
NCT00651833 2024-09-03

Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer

Taiho Oncology, Inc.

Phase 2 Completed
60 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

NCT00652561 2024-09-03

Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer

Taiho Oncology, Inc.

Phase 2 Completed
57 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡